Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Optaflu (2012/2013 Formulation) in Adults and Elderly
NCT01640314Phase 3Completed
- Sponsor
- Novartis
- Start
- Jul 2012
- Primary completion
- Aug 2012
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of TIVc in influenza, sponsored by Novartis. Primary endpoints: Percentages of Subjects With Seroconversion or Significant Increase in HI Titer Against Each of Three Vaccine Strains at Day 22, Geometric Mean Ratio of Subjects Against Each of Three Vaccine Strains at Day 22 and 1 more. Started Jul 2012; status: completed.
02
Drugs
TIVc
03
Conditions
influenza
Beyond the preview
Go deeper on NCT01640314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01640314.